The present authors carried out an open up-label pilot review that administered psilocybin to fifteen treatment-resistant tobacco/nicotine-dependent smokers, while in the context of cognitive behavioral therapy for smoking cigarettes cessation [fifty eight]. Members ended up administered ~0.29 mg/kg oral psilocybin over the participant’s focus on